Amarin Corp Plc (AMRN)

[jessellivermore]

Atom...

Quote: "FDA is convening an AdCom because they do not think a 12% relative risk reduction in cardiovascular outcomes is sufficient for expanding the label to include the primary prevention cohort (i.e., patients had diabetes mellitus and at least one additional risk factor)."

And just how did you come to that conclusion..I do believe the AdCom will address the question of what the drug indication will be...I would be very surprised if it rules out Primsry Prevention particularly the way you see it..

Are you an MD?

":>) JL